Lipid Panel (Total Cholesterol, LDL-C, HDL-C, Triglycerides, Non-HDL-C)

Total cholesterol is the aggregate measurement of all cholesterol carried within circulating lipoprotein particles — including LDL, HDL, VLDL, IDL, and chylomicron remnants — in serum. Cholesterol is an essential membrane structural lipid, the precursor to steroid hormones, bile acids, and vitamin D, synthesised endogenously by the liver (approximately 70–80% of circulating cholesterol) under HMG-CoA reductase regulation, and absorbed from dietary sources in the small intestine via the NPC1L1 transporter. Total cholesterol measurement by the enzymatic colorimetric method (cholesterol oxidase-peroxidase, CHOD-PAP) quantifies the sum of all lipoprotein-associated cholesterol in a single value that does not differentiate atherogenic from anti-atherogenic fractions — a limitation addressed by interpretation of the full lipid panel rather than total cholesterol in isolation.

Total cholesterol is the entry-level lipid screening value and a component of cardiovascular risk scores including the Pooled Cohort Equations (PCE), SCORE2, and Reynolds Risk Score. It is used as a population-level triage marker — values above 200 mg/dL flag individuals for full lipid panel assessment — but carries limited independent clinical actionability in isolation because the same total cholesterol value can reflect either high LDL-C with low HDL-C (atherogenic) or high HDL-C with low LDL-C (relatively protective). Total cholesterol above 240 mg/dL warrants full lipid panel characterisation regardless of prior assessment. The cholesterol:HDL ratio — total cholesterol divided by HDL — is a derived index with modest independent predictive value used in some risk frameworks, though non-HDL cholesterol and ApoB are clinically superior risk markers.

LDL particles are the primary carriers of cholesterol to peripheral tissues, generated from VLDL through sequential lipolysis by lipoprotein lipase and hepatic lipase, with IDL as an intermediate form. Each LDL particle contains a single apolipoprotein B-100 (ApoB-100) molecule, which mediates binding to hepatic and peripheral LDL receptors for receptor-mediated endocytosis. LDL-C as measured in the standard lipid panel is a cholesterol mass measurement — the total cholesterol load carried within LDL particles — rather than a particle count. LDL particle number (LDL-P) and ApoB are more direct measures of the atherogenic particle burden, as the same LDL-C value can correspond to different particle numbers depending on particle size: small, dense LDL particles carry less cholesterol per particle than large, buoyant LDL, so individuals with LDL-C:LDL-P discordance may have substantially higher atherogenic risk than their LDL-C suggests.

LDL-C is the most extensively validated modifiable ASCVD risk factor and the primary pharmacological target of lipid-lowering therapy across all major cardiovascular guidelines. The causal relationship between LDL-C and ASCVD is established through Mendelian randomisation studies in familial hypercholesterolaemia and hypocholesterolaemia populations, statin and PCSK9 inhibitor trial data, and epidemiological cohort analysis — with each 1 mmol/L (approximately 39 mg/dL) reduction in LDL-C associated with approximately 22% relative risk reduction in major adverse cardiovascular events (MACE). In the full lipid panel, LDL-C drives the key clinical decision: whether to initiate lipid-lowering pharmacotherapy, at what intensity, and to what treatment target — with risk-stratified targets ranging from <100 mg/dL in primary prevention with risk factors to <55 mg/dL in very-high-risk established ASCVD patients per 2019 ESC/EAS guidelines.

HDL particles are the smallest and most dense circulating lipoprotein class, synthesised by the liver and intestine and remodelled extensively in the circulation. They mediate reverse cholesterol transport — accepting free cholesterol from peripheral tissues and arterial macrophage foam cells via the ATP-binding cassette transporters ABCA1 and ABCG1, esterifying it via LCAT, and transferring it to the liver for excretion via CETP-mediated transfer to LDL and direct hepatic scavenger receptor BI (SR-BI) uptake. HDL particles also exert direct anti-atherogenic effects through anti-inflammatory, antioxidant, and endothelial protective mechanisms. HDL-C, however, measures only cholesterol mass within HDL particles — not HDL particle number or HDL functional capacity — and has shown less consistent therapeutic utility than LDL-C as a drug target, with HDL-raising drugs (niacin, CETP inhibitors) failing to reduce cardiovascular events despite raising HDL-C in clinical trials.

HDL-C is a negative cardiovascular risk factor — lower HDL-C values are associated with higher ASCVD risk in epidemiological data, and HDL-C below 40 mg/dL (males) or 50 mg/dL (females) constitutes a component of the metabolic syndrome definition. Within the lipid panel, HDL-C contributes to non-HDL-C calculation (TC − HDL-C) and total cholesterol:HDL ratio. In the context of dyslipidaemia characterisation, low HDL-C alongside elevated triglycerides and relatively preserved LDL-C is the characteristic atherogenic dyslipidaemia of insulin resistance and metabolic syndrome — a pattern that confers ASCVD risk underestimated by LDL-C alone and is better captured by non-HDL-C and ApoB. Very high HDL-C (>80 mg/dL in males, >90 mg/dL in females) may paradoxically be associated with increased cardiovascular risk through dysfunctional HDL mechanisms — practitioners should interpret extreme HDL elevations clinically rather than assuming proportional cardiovascular protection.

Triglycerides (triacylglycerols) are glycerol esters of three fatty acid chains — the principal form of dietary fat storage and the primary energy substrate delivered by the hepatic VLDL secretory pathway to peripheral tissues. Postprandially, dietary triglycerides are packaged into chylomicrons in the intestine and cleared from the circulation within 4–6 hours by lipoprotein lipase on endothelial surfaces. In the fasting state, serum triglycerides reflect predominantly hepatic VLDL-TG production, regulated by insulin and dietary carbohydrate intake. Elevated VLDL production from caloric excess, insulin resistance, or genetic dyslipidaemia (familial hypertriglyceridaemia, lipoprotein lipase deficiency) produces fasting hypertriglyceridaemia. Triglycerides above 400 mg/dL invalidate the Friedewald LDL-C equation; above 1,000 mg/dL carry significant pancreatitis risk.

Triglycerides are the lipid panel parameter most directly responsive to diet and lifestyle — they fall rapidly with carbohydrate restriction, exercise, alcohol elimination, and weight reduction, making them the most sensitive marker of dietary and lifestyle intervention response in the lipid panel. In ASCVD risk assessment, elevated triglycerides — particularly in the context of low HDL-C and relatively normal LDL-C — characterise the atherogenic dyslipidaemia of insulin resistance and metabolic syndrome. Elevated triglycerides are associated with increased remnant cholesterol (IDL and chylomicron remnant cholesterol) and small dense LDL particles, both of which contribute to ASCVD risk beyond LDL-C. Very high triglycerides (>500 mg/dL) confer acute pancreatitis risk independent of ASCVD risk and require urgent clinical management. Triglyceride measurement is the necessary denominator for Friedewald LDL-C calculation and the primary indicator of Friedewald equation reliability.

Non-HDL cholesterol is a mathematically derived value — total cholesterol minus HDL cholesterol — capturing cholesterol carried in all atherogenic lipoprotein particles simultaneously: LDL, VLDL, IDL, lipoprotein(a), and chylomicron remnants. Because each of these particle types carries a single ApoB-100 (or ApoB-48 for chylomicrons) molecule, non-HDL-C provides an integrated measure of the total atherogenic lipoprotein cholesterol burden that includes the full atherogenic particle spectrum, unlike LDL-C which captures only the LDL fraction. Non-HDL-C requires no calculation assumptions or fasting specimen corrections — it is derivable from any lipid panel regardless of fasting status or triglyceride level, making it the preferred lipid target in non-fasting specimens.

Non-HDL-C is endorsed by ACC/AHA 2018, ESC/EAS 2019, and NLA guidelines as a secondary lipid target that is superior to LDL-C for total atherogenic burden characterisation — particularly in patients with hypertriglyceridaemia and metabolic syndrome, where LDL-C underestimates the atherogenic particle burden represented by VLDL and IDL remnant cholesterol. Non-HDL-C is the single most practical risk marker in non-fasting specimens, where LDL-C Friedewald calculation is unreliable. In the full lipid panel, non-HDL-C should be interpreted alongside LDL-C — when non-HDL-C is disproportionately elevated relative to LDL-C (non-HDL-C − LDL-C >30 mg/dL), it signals elevated remnant cholesterol from VLDL and IDL, the lipid phenotype of insulin resistance and metabolic syndrome, warranting triglyceride reduction strategies in addition to LDL-C management.

VLDL (very low-density lipoprotein) particles are assembled by the liver from triglycerides, cholesterol, and apolipoprotein B-100, and secreted into the circulation as the primary vehicle for hepatic triglyceride export to peripheral tissues. Each VLDL particle carries one ApoB-100 molecule. As VLDL-TG is hydrolysed by lipoprotein lipase, the particles progressively shrink and enrich in cholesterol, transitioning through IDL to LDL. VLDL-C is estimated in the standard lipid panel as triglycerides ÷ 5, based on the average TG:cholesterol ratio of VLDL particles — an assumption that becomes unreliable when triglycerides are markedly elevated or when a large proportion of the triglyceride pool is in non-VLDL particles.

VLDL-C as a discrete clinical parameter has limited independent clinical utility in the standard lipid panel beyond its role in the Friedewald LDL-C equation. Elevated VLDL-C above 40 mg/dL reflects hypertriglyceridaemia and increased hepatic VLDL output — typically driven by insulin resistance, caloric excess, alcohol, or genetic dyslipidaemia. In the broader cardiovascular risk context, VLDL remnant particles (IDL) are directly atherogenic independently of LDL; the remnant cholesterol concept — calculating remnant cholesterol as non-HDL-C minus LDL-C — captures the VLDL and IDL atherogenic contribution beyond LDL-C and is gaining traction as a clinical risk marker in metabolic syndrome.